[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CN1352554A - IL-8 receptor antagaonists - Google Patents

IL-8 receptor antagaonists Download PDF

Info

Publication number
CN1352554A
CN1352554A CN00808133A CN00808133A CN1352554A CN 1352554 A CN1352554 A CN 1352554A CN 00808133 A CN00808133 A CN 00808133A CN 00808133 A CN00808133 A CN 00808133A CN 1352554 A CN1352554 A CN 1352554A
Authority
CN
China
Prior art keywords
alkyl
aryl
heteroaryl
thiazolinyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00808133A
Other languages
Chinese (zh)
Inventor
M·R·帕洛维奇
K·L·威多森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of CN1352554A publication Critical patent/CN1352554A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This invention relates to the novel use of phenyl ureas in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

Description

The IL-8 receptor antagonist
Invention field
The present invention relates to ring guanidine compound, its preparation method, its purposes in the disease of treatment IL-8, GRO α, GRO β, GRO γ, NAP-2 and ENA-78 mediation and the pharmaceutical composition that is used for this therapy of one group of novelty.
Background of invention
Interleukin 8 (IL-8) has many different titles, lure/activated protein-1 (NAP-1) such as neutrophilic granulocyte, come from monocytic neutrophilic chemotactic factor (MDNCF), the neutrophilic granulocyte activation factor (NAF) and T cell lymphocyte chemotactic factor.Interleukin 8 is the chemical inhibitor to neutrophilic granulocyte, basophil and T cell subsets, it is by comprising that the huge most nucleated cell of having a liking for cell, fibroblast, endotheliocyte and epithelial cell that are exposed to TNF, IL-1 α, IL-1 β or LPS produce, and by being exposed to LPS or being produced such as the neutrophilic granulocyte of the chemotactic factor of FMLP itself.M.Baggiolini etc., J.Clin.Invest.84,1045 (1989); J.Schroder etc., J.Immunol.139,3474 (1987) and J.Immunol.144,2223 (1990): Strieter etc., Science 243,1467 (1989) and J.Biol.Chem.264,10621 (1989); Cassatella etc., J.Immunol.148,3216 (1992).
Gro α, GRO β, GRO γ and NAP-2 also belong to chemokine alpha family, as IL-8, these chemotactic factors are also by titled with different titles, for example GRO α, β, γ are called as MGSA α, β and γ (melanoma growth-stimulating activity (Melanoma GrowthStimulating Activity)) respectively, see Richmond etc., J.Cell Physiology129,375 (1986) and Chang etc., J.Immunol 148,451 (1992).All chemotactic factors that have a α family that is located immediately at the ELR motif before the CXC motif all with the IL-8B receptors bind.
External, IL-8, Gro α, GRO β, GRO γ, NAP-2 and ENA-78 have promoted many functions, and they all demonstrate the granulocytic chemical attractants characteristic of neutrality, and IL-8 and GRO α demonstrate T-lymphocyte and basophil chemotactic activity simultaneously.In addition, IL-8 can induce the basophil of normal and atopic individuality to discharge histamine.In addition, IL-8 and GRO-α can induce the lysozyme of neutrophilic granulocyte to discharge and respiratory burst.IL-8 also demonstrates has increased Mac-1 (CD11b/CD18) surface expression at neutrophilic granulocyte when not having de novo albumen synthetic.This can help to increase the adhesive attraction of neutrophilic granulocyte and vascular endothelial cell.Many known diseases are to be feature with a large amount of neutrophil infiltration.Promote gathering and activating of neutrophilic granulocyte as IL-8, Gro α, GRO β, GRO γ and NAP-2, these chemotactic factors are relevant with the very large-scale acute and chronic inflammation disease that comprises psoriasis and rheumatic arthritis, Baggiolini etc., FEBS Lett.307,97 (1992); Miller etc., Crit.Rev.Immunol.12,17 (1992); Oppenheim etc., Annu Rev.Immunol.9,617 (1991); Seitz etc., J.Clin.Invest.87,463 (1991); Miller etc., Am.Rev.Respir.Dis.146,427 (1992); Donnely etc., Lancet 341,643 (1993).In addition, ELR chemotactic factor (those just in time before the CXC motif contain aminoacid ELR motif) is also relevant with antagonist, Strieter etc., and Science 258,1798 (1992).
External, by in conjunction with and activate the receptor of striding the G albumen coupling family of film for seven times, particularly pass through in conjunction with the IL-8 receptor, the most significant is the B receptor, and IL-8, Gro α, GRO β, GRO γ and NAP-2 induce neutrophilic granulocyte alteration of form, chemotaxis, particle release and respiratory burst, Thomas etc., J.Biol.Chem.266,14839 (1991) and Holmes etc., Science 253,1278 (1991).The development of this receptor family member's non-peptide micromolecule antagonist has had precedent, and its summary sees that R.Freidinger is at Progress inDrug Research, Vol.40, pp.33-98, Birkhauser Verlag, Basel1993.Therefore, the IL-8 receptor has been represented the target full of hope of novel anti-inflammatory drug development.
The feature of the human IL-8 receptor (77% homology) of two kinds of high-affinities is as follows: only with the bonded IL-8R α of IL-8 high-affinity, and the IL-8RB that IL-8 and GRO α, GRO β, GRO γ and NAP-2 is all had high-affinity.See Holmes etc., see above; Murphy etc., Science 253,1280 (1991); Lee etc., J.Biol.Chem.267,16283 (1992); LaRosa etc., J.Biol.Chem.267,25402 (1992); With Gayle etc., J.Biol.Chem.268,7283 (1993).
In this field, to the treatment also need can with IL-8 α or the bonded chemical compound of beta receptor.Therefore, the chemical compound of the inhibitor of IL-8 receptors bind will be useful to increase (it is responsible for neutrophilic granulocyte and T cell subsets chemotactic are arrived areas of inflammation) relevant disease with the IL-8 generation.
Summary of the invention
The invention provides a kind of method for the treatment of chemokine mediated diseases, wherein, chemotactic factor and IL-8 α or beta receptor combination, and the method comprises formula (I) compound or pharmaceutically acceptable salt thereof of using effective dose.Particularly this chemotactic factor is IL-8.
The invention still further relates to the method for needs inhibition IL-8 and its receptors bind in mammal, it comprises the chemical compound to the formula of above-mentioned administration effective dose (I).
Be used for formula of the present invention (I) chemical compound and have following structure: Wherein:
R is OH, SH, NHSO 2R d
R dBe NR 6R 7, alkyl, aryl C 1-4Alkyl, aryl C 2-4Thiazolinyl, heteroaryl, heteroaryl C 1-4Alkyl, heteroaryl C 2-4Thiazolinyl, heterocyclic radical, heterocyclic radical C 1-4Alkyl, wherein aryl, heteroaryl and heterocycle all can be optionally substituted.
R 6And R 7Be hydrogen or C independently 1-4Alkyl group, or R 6And R 7Form 5 to 7 yuan of rings together with the nitrogen that is attached thereto, this ring can be chosen wantonly and comprise the hetero atom that another is selected from oxygen, nitrogen or sulfur, and this ring can be optionally substituted;
R 1Independently be selected from hydrogen, halogen, nitro, cyano group, halo C 1-10Alkyl, C 1-10Alkyl, C 2-10Thiazolinyl, C 1-10Alkoxyl, halo C 1-10Alkoxyl, azide, (CR 8R 8) qS (O) tR 4, hydroxyl, hydroxyl C 1-4Alkyl, aryl, aryl C 1-4Alkyl, aryloxy group, aryl C 1-4Alkoxyl, heteroaryl, heteroaryl alkyl, heterocyclic radical, heterocyclic radical C 1-4Alkyl, heteroaryl C 1-4Alkoxyl, aryl C 2-10Thiazolinyl, heteroaryl C 2-10Thiazolinyl, heterocycle C 2-10Thiazolinyl, (CR 8R 8) qNR 4R 5, C 2-10Thiazolinyl C (O) NR 4R 5, (CR 8R 8) qC (O) NR 4R 5, (CR 8R 8) qC (O) NR 4R 10, S (O) 3H, S (O) 3R 8, (CR 8R 8) qC (O) R 11, C 2-10Thiazolinyl C (O) R 11, C 2-10Thiazolinyl C (O) OR 11(CR 8R 8) qC (O) OR 12, (CR 8R 8) qOC (O) R 11, (CR 8R 8) qNR 4C (O) R 11, (CR 8R 8) qNHS (O) 2R 17, (CR 8R 8) qS (O) 2NR 4R 5, or two R 1Common O-(the CH that forms of part 2) sO-or undersaturated 5 to 6 yuan of rings;
Q is 0 or the integer of 1-10;
T is 0 or 1 or 2 integer;
S is the integer of 1-3;
R 4And R 5Independently be hydrogen, the optional C that replaces 1-4Alkyl, the optional aryl that replaces, the optional aryl C that replaces 1-4Alkyl, the optional heteroaryl that replaces, the optional heteroaryl C that replaces 1-4Alkyl, heterocyclic radical, heterocyclic radical C 1-4Alkyl or R 4And R 5Form 5 to 7 yuan of rings together with the nitrogen that is attached thereto, this ring can be chosen wantonly and comprise the hetero atom that another is selected from oxygen, nitrogen or sulfur;
R 2Be independently selected from: C 2-5Alkyl and C 2-5Thiazolinyl, its all groups can be chosen wantonly independently by following groups one to three replacement: halogen, nitro, halo C 1-4Alkyl, C 1-4Alkyl, amino, list-or two-C 1-4Amine, hydroxyl, C that alkyl replaces 1-4Alkoxyl, NR 9C (O) Ra, S (O) mR a, C (O) NR 6R 7, C (O) OH, C (O) OR a, S (O) 2NR 6R 7, NHS (O) 2R a, and de-carbon outside optional independently contain 1 to 3 NR 9, O, C (O), S, SO or SO 2Part;
Y is independently selected from: hydrogen, halogen, nitro, cyano group, halo C 1-10Alkyl, C 1-10Alkyl, C 2-10Thiazolinyl, C 1-10Alkoxyl, halo C 1-10Alkoxyl, azide, (CR 8R 8) qS (O) tR 4, hydroxyl, hydroxyl C 1-4Alkyl, aryl, aryl C 1-4Alkyl, aryloxy group, aryl C 1-4Alkoxyl, heteroaryl, heteroaryl alkyl, heteroaryl C 1-4Alkoxyl, heterocyclic radical, heterocyclic radical C 1-4Alkyl, aryl C 2-10Thiazolinyl, heteroaryl C 2-10Thiazolinyl, heterocyclic radical C 2-10Thiazolinyl, (CR 8R 8) qNR 4R 5, C 2-10Thiazolinyl C (O) NR 4R 5, (CR 8R 8) qC (O) NR 4R 5, (CR 8R 8) qC (O) NR 4R 10, S (O) 3H, S (O) 3R 8, (CR 8R 8) qC (O) R 11, C 2-10Thiazolinyl C (O) R 11, C 2-10Thiazolinyl C (O) OR 11C (O) R 11, (CR 8R 8) qC (O) OR 12, (CR 8R 8) qOC (O) R 11, (CR 8R 8) qNR 4C (O) R 11, (CR 8R 8) qNHS (O) 2R d, (CR 8R 8) qS (O) 2NR 4R 5, or two Y part can together form O-(CH 2) sO-or undersaturated 5 to 6 yuan of rings;
N is the integer of 1-3;
M is the integer of 1-3;
R 8Be hydrogen or C 1-4Alkyl;
R 9Be hydrogen or C 1-4Alkyl;
R 10Be C 1-10Alkyl C (O) 2R 8
R 11Be hydrogen, C 1-4Alkyl, the optional aryl that replaces, the optional aryl C that replaces 1-4Alkyl, the optional heteroaryl that replaces, the optional heteroaryl C that replaces 1-4Alkyl, the optional heterocyclic radical that replaces or the optional heterocyclic radical C that replaces 1-4Alkyl;
R 12Be hydrogen, C 1-10Alkyl, the optional aryl that replaces or the optional aryl alkyl that replaces;
R 17Be C 1-4Alkyl, aryl, aryl alkyl, heteroaryl, heteroaryl C 1-4Alkyl, heterocyclic radical or heterocyclic radical C 1-4Alkyl, wherein aryl, heteroaryl and heterocycle all can be chosen wantonly and be substituted; And
R aBe alkyl, aryl, aryl C 1-4Alkyl, heteroaryl, heteroaryl C 1-4Alkyl, heterocyclic radical or heterocyclic radical C 1-4Moieties, all these parts all can be optionally substituted.
Detailed Description Of The Invention
The chemical compound of formula (I) also can be used for and mammal, except the mankind, veterinary's treatment relevant, need to suppress IL-8 or with other chemotactic factor of IL-8RA and RB receptors bind in.Treatment or prevention comprise chemokine mediated disease those diseases as partly mentioning at this paper Therapeutic Method in animal.
The typical compound of formula (I) comprising:
4-[[1-(2-bromophenyl)-4,5-dihydro-5-oxo-1H-imidazoles-2-yl] amino]-the 3-hydroxy benzonitrile,
N-(4-cyano-2-hydroxy-phenyl)-N '-(2-bromophenyl)-N " (2-ethoxy) guanidine,
N-(4-cyano-2-hydroxy-phenyl)-N '-(2-bromophenyl)-N " (chloromethanes sulfonyl) guanidine,
N-(4-cyano-2-hydroxy-phenyl)-N '-(2-bromophenyl)-N " (2, the 2-dimethoxy-ethyl) guanidine,
4-[[1-(2-bromophenyl)-4,5-dihydro-1H-imidazoles-2-yl] amino]-the 3-hydroxy benzonitrile,
4-[[4-(2-bromophenyl)-4,5-dihydro-1,1-diepoxy-1,2,4-thiadiazoles-3-yl] amino]-the 3-hydroxy benzonitrile,
4-[[1-(2-bromophenyl)-1H-imidazoles-2-yl] amino]-the 3-hydroxy benzonitrile,
4-[(S)-1-(2-bromophenyl)-4-isopropyl-5-oxo-4,5-dihydro-1H-imidazoles-2-base is amino]-3-hydroxyl-benzonitrile,
3-[(S)-and 1-(2-bromophenyl)-2-(4-cyano-2-hydroxy-phenyl amino)-5-oxo-4,5-dihydro-1H-imidazol-4 yl]-ethyl propionate,
[(R)-and 1-(2-bromophenyl)-2-(4-cyano-2-hydroxy--phenyl amino)-5-oxo-4,5-dihydro-1H-imidazol-4 yl]-ethyl acetate,
4-[(S)-1-(2, the 3-Dichlorobenzene base)-4-isopropyl-5-oxo-4,5-dihydro-1-H-imidazoles-2-base is amino]-the 3-hydroxy benzonitrile,
4-[(S)-1-(2, the 3-Dichlorobenzene base)-4-isobutyl group-5-oxo-4,5-dihydro-1H-imidazoles-2-base is amino]-the 3-hydroxy benzonitrile,
4-[(S)-1-(2, the 3-Dichlorobenzene base)-4-(2-methyl sulphonyl (sulfanyl) ethyl)-5-oxo-4,5-dihydro-1H-imidazoles-2-base is amino]-the 3-hydroxy benzonitrile,
3-[(S)-and 2-(4-cyano-2-hydroxy-phenyl amino)-1-(2, the 3-Dichlorobenzene base)-5-oxo-4,5-dihydro-1H-imidazol-4 yl]-ethyl propionate,
4-[(S)-1-(2, the 3-Dichlorobenzene base)-4-methyl-5-oxo-4,5-dihydro-1H-imidazoles-2-base is amino]-the 3-hydroxy benzonitrile,
4-[(R)-1-(2, the 3-Dichlorobenzene base)-4-methyl-5-oxo-4,5-dihydro-1H-imidazoles-2-base is amino]-the 3-hydroxy benzonitrile and
4-[[1-(2-bromophenyl)-4,5-dihydro-5-methoxyl group-1H-imidazoles-2-yl] amino]-the 3-hydroxy benzonitrile; Or its suitable acceptable salt.
Suitable officinal salt be well known to those skilled in the art those, and comprise inorganic or organic acid basic salt (basic salts), acid as: hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulfonic acid, ethyl sulfonic acid, acetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid and mandelic acid.In addition, the officinal salt of formula (I) chemical compound can also form with pharmaceutically useful cation, for example, if contain a carboxyl in a substituent group.Suitable pharmaceutically acceptable cation is well known to those skilled in the art, and comprises: alkali, alkaline earth, ammonium and quaternary ammonium cation.
Following term used herein is meant:
● " halogen "-all halogens, i.e. chlorine, fluorine, bromine and iodine.
● " C2-5 alkyl " or " alkyl "-all refer to the straight or branched part of 2-5 carbon atom, unless chain length is had qualification in addition, it includes but not limited to methyl, ethyl, n-pro-pyl, isopropyl, normal-butyl, sec-butyl, isobutyl group, the tert-butyl group, n-pentyl etc.
● term used herein " thiazolinyl " all refers to the straight or branched part of 2-10 carbon atom in all cases, unless chain length is had qualification in addition, includes but not limited to vinyl, 1-acrylic, 2-acrylic, 2-methyl isophthalic acid-acrylic, 1-butylene base, crotyl etc.
● " aryl "-phenyl and naphthyl;
● " heteroaryl " is (in itself or any associating, such as " heteroaryl oxygen base " or " heteroaryl alkyl ")-5-10 unit aromatic ring system, wherein one or more rings contain the hetero atom of one or more N of being selected from, O or S, for example, but be not limited to pyrroles, pyrazoles, furan, thiophene, quinoline, isoquinolin, quinazoline, pyridine, pyrimidine, oxazole, thiazole, thiadiazoles, triazole, imidazoles or benzimidazole.
● " heterocycle " is (in itself or any associating, such as " Heterocyclylalkyl ")-the saturated or undersaturated 4-10 of part unit member ring systems, wherein one or more rings contain the hetero atom of one or more N of being selected from, O or S, for example, but be not limited to pyrrolidine, piperidines, piperazine, morpholine, Pentamethylene oxide. and imidazoline.
Term used herein " aryl alkyl " or " heteroaryl alkyl " or " Heterocyclylalkyl " do not refer to C as defined above if there is other explanation 1-10Alkyl is connected on aryl defined herein, heteroaryl or the heterocyclic radical part.Preparation method
Can use the chemical compound of synthetic method, illustrate in the some of them method route hereinafter with acquisition formula (I).The synthetic method that provides in these routes can be used for the chemical compound of production formula (I), and it has various R, the R that reacts 1, and aryl, and use by the optional substituent group of due care to reach consistent with listed reaction herein.In these cases, deprotection obtains former chemical compound of the present disclosure subsequently.In case constitute guanidine nuclear, other chemical compounds of these formulas just can prepare by the standard technique that functional group known in the art transforms.And the chemical compound that has only formula (I) that these routes show, this only is in order to illustrate.
Route 1
Figure A0080813300121
A) Br 2, NaOAc, HOAc; B) CuCN, DMF refluxes; C) (BOC) 2O, DMAP, TEA; D) K 2CO 3, MeOH; E) TFA
Purpose aniline 6-route-1 can be with being purchased the preparation of benzoxazolinone 1-route-1.Bromide 2-route-1 can be with benzoxazolinone 1-route-1 in standard bromination condition, as preparing with bromine and sodium acetate bromination in acetic acid.Bromide 2-route-1 available standards method such as Cupricin. (I) reflux in DMF and change into cyanide 3-route-1.Amide 3-route-1 can be used standard conditions, in dichloromethane or other suitable organic solvent, changes into the chemical compound 4-route-1 of BOC protection such as the dimethylamino naphthyridine of BOC acid anhydride and triethylamine and catalytic amount.Oxazoline 4-route-1 can be by using standard conditions; as potassium carbonate in methanol; at first be hydrolyzed into phenol 5-route-1, use standard conditions then, obtain purpose aniline 6-route-1 as in dichloromethane or other suitable organic solvent, the BOC protecting group being taken off with trifluoroacetic acid.
Route 2 A) RNCS; B) TBSCI; C) thio phosgene; D) RNH2
Purpose thiourea 3-route-2 can prepare according to route 2 listed methods.Aniline 1-route-2 can be connected with isothiocyanate that thiophosgene or the condensation of thiophosgene equivalent obtain with the isothiocyanate that is purchased or from the amine that is purchased and obtains thiourea 2-route-2.Phenol 2-route-2 can be in THF or other suitable organic solvent be become TBS ether 3-route-2 by protected under the standard conditions such as TBSCl and imidazoles.In addition; amine 1-route-2 can be at first with suitable protecting group such as TBS ether 4-route-2; with standard conditions for example in THF or other suitable organic solvent such as TBSCl and amine alkali, as imidazoles protection phenol 1-route-2, can be converted to isothiocyanate 5-route-2., condensation in the presence of alkali such as potassium carbonate can prepare thiourea 5-route-2 by amine 4-route-2 and thiophosgene.Purpose thiourea 3-route-2 can by isothiocyanate 5-route-2 in suitable organic solvent such as among ethanol or the DMF with the amine condensation prepared of purpose.
Route 3
Figure A0080813300141
Purpose lactams 3-route-3 can prepare according to route 3 listed methods.Carbodiimides 2-route-3 can be in standard conditions, as at room temperature, at organic solvent, in the preferred dichloromethane, with thiourea 1-route-3 and excessive methane sulfonyl chloride and suitable amine alkali, prepare as triethylamine.Lactams 3-route-3 can at first pass through the alpha-amido ester of carbodiimides 2-route-3 and purpose in appropriate organic solvent with carbodiimides 2-route-3, as condensation in THF or the acetonitrile, use standard conditions then, in 0 ℃ THF, take off the TBS group as TBAF and make.
Route 4
Figure A0080813300151
A) 2-ethylaminoethanol, Hunig ' s alkali, THF; B) TBAF, THF; C) PPh 3, DEAD, THF
Purpose glyoxalidine guanidine (dihydroimidazoyl guanidine) 3-route-4 can prepare with pure 2-route-4 according to the method shown in the route 4.Guanidine 2-route-4 can as by in appropriate organic solvent, as adding primary amine among acetonitrile or the THF, then in standard conditions, be taken off the TBS group as TBAF and make with carbodiimides 1-route-4 in standard conditions in 0 ℃ THF.Ring guanidine 3-route-4 can be with the Mitsunobu condition of standard, as triphenyl phasphine and DEAD in suitable organic solvent such as THF, with the preparation of guanidine 2-route-4.
Route 5
Figure A0080813300161
A) chloromethanes sulfonamide, Hunig ' s alkali, THF; B) TBAF, THF; C) NaH, DMF
Purpose cyclic sulfonamides guanidine 3-route-5 can prepare with chloride 2-route-5 according to method shown in the route 5.Guanidine 2-route-5 can prepare with carbodiimides 1-route-5 by the condition of describing in route 3 and 4.The alkylation conditions of ring guanidine 3-route-5 available standards, prepares as using chloride 2-route-5 among the DMF, under room temperature or slightly heated in appropriate organic solvent as NaH.
Route 6
Figure A0080813300171
A) 2,2-dimethoxy-ethylamine, Hunig ' s alkali, THF; B) TBAF, THF; C) pTSA, acetone
Imidazoles guanidine 3-route-6 can, prepare with dimethylacetal 2-route-6 in suitable organic solvent such as acetone as pTSA under the standard acidic condition.Guanidine 2-route-6 can prepare with carbodiimides 1-route-6 according to route 3 and 4 methods of describing.
Synthetic embodiment
The present invention will be described by the following example, and these embodiment are illustrative, and can not be interpreted as the restriction to field of the present invention.Unless otherwise indicated, all degree centigrade to provide, all solvents all are obtainable highest purities to all temperature, and respond and all under argon atmospher, anhydrous condition, carry out.
In these embodiments, all temperature be degree centigrade (℃).Unless otherwise indicated, mass spectrum is to use fast atom bombardment, measures on VG Zab mass spectrograph. 1H-NMR (hereinafter for " NMR ") spectrum be with on Bruker AM 250 or Am 400 spectrometers under 250MHz record.Represented multiplet is: s=is unimodal, d=is bimodal, t=triplet, q=quartet, m=multiplet and br represent wide signal.Sat. refer to saturated solution, eq refers to the molar equivalent ratio of reagent with respect to the dominant response thing.
Embodiment 14-[[1-(2-bromophenyl)-4.5-dihydro-5-oxo-1H-imidazoles-2-yl] amino]-preparation of 3-hydroxy benzonitrile.A) the 4-bromo-1, the preparation of 2-benzoxazolinone.
0 ℃ to benzoxazolinone (10g, add in acetic acid 74mmol) (50ml) solution sodium acetate (7.4g, 74mmol) and bromine (3.8ml, 74mmol) and with the reactant mixture temperature to room temperature.After 21 hours, by filtering the collecting precipitation thing and washing with water.Filtrate under reduced pressure concentrates, and filters to collect to obtain more solid matter, washes with water then.Merge the 4-bromo-1 that this material obtains 14g (88%), 2-benzoxazolinone yellow solid, this product do not need to be further purified. 1H?NMR(400MHz，DMSO)δ7.6(s，1H)，7.3(d，1H)，7.0(d，1H)；MS(EI)m/e?212(M +)。B) 4-cyano group-1, the preparation of 2-benzoxazolinone.
To 4-bromo-1, the 2-benzoxazolinone (5.0g, add in DMF 23mmol) (11mL) solution Cupricin. (I) (3.6g, 39mmol), and 165 ℃ of heating.6.5 after hour, with this reactant mixture cool to room temperature, and add entry (20ml) and Cyanogran. (3.6g), and reaction be heated to 100 ℃.After 12 hours, use the ethyl acetate extraction reactant mixture, the column scrubber of the organic layer of merging through being filled with silica gel filters, and uses eluent ethyl acetate.Filtrate decompression concentrates and obtains 1.9g (51%) 4-cyano group-1, and the brown solid of 2-benzoxazolinone, this product do not need to be further purified. 1H?NMR(400MHz，DMSO)δ7.8(s，1H)，7.6(d，1H)，7.2(d，1H)。C) N-tert-butyl group acetoxyl group-4-cyano group-1, the preparation of 2-benzoxazolinone.
Under 0 ℃, to 4-cyano group-1, the 2-benzoxazolinone (1.9g, add in THF 15mmol) (50mL) solution triethylamine (2.5mL, 18mmol), DMAP (0.37g, 3.0mmol) and the BOC acid anhydride (4.3g, 20mmol) and with this reactant mixture temperature to room temperature.1.5 after hour, water (100mL) stopped reaction is also used ethyl acetate extraction, the organic layer salt water washing that merges, use anhydrous magnesium sulfate drying, and concentrating under reduced pressure obtains 4.3g (100%) N-tert-butyl group acetoxyl group-4-cyano group-1,2-benzoxazolinone yellow solid, this product do not need to be further purified. 1H?NMR(400MHz，CDCl 3)δ7.8(d，1H)，7.55(d，1H)，7.45(s，1H)，1.65(s，9H)。D) preparation of N-tert-butyl group acetoxyl group-4-cyano-2-hydroxy-aniline.
To N-tert-butyl group acetoxyl group-4-cyano group-1, the 2-benzoxazolinone (4.3g, add in methanol 16mmol) (50mL) solution potassium carbonate (2.3g, 16mmol).1.5 after hour, water (100mL) cessation reaction, and use ethyl acetate extraction.Anhydrous magnesium sulfate drying is used in the organic layer salt water washing that merges, and concentrating under reduced pressure obtains the brown foamed N-tert-butyl group acetoxyl group of 3.1g (81%)-4-cyano-2-hydroxy-aniline, and this product does not need to be further purified. 1H?NMR(400MHz，CDCl 3)δ7.7(d，1H)，7.15(s，1H)，7.1(d，1H)，1.5(s，9H)。E) preparation of 4-cyano-2-hydroxy-aniline.
0 ℃ to N-tert-butyl group acetoxyl group-4-cyano-2-hydroxy-aniline (3.1g, add trifluoroacetic acid in dichloromethane 13mmol) (100mL) solution and with the reactant mixture temperature to room temperature.2.5 after hour, water (100mL) cessation reaction, and use ethyl acetate extraction, the salt water washing of the organic layer of merging is with anhydrous magnesium sulfate drying and concentrating under reduced pressure.Crude product obtains 1.7g (96%) 4-cyano-2-hydroxy-aniline brown solid with flash column chromatography purification (50% ethyl acetate/hexane). 1H?NMR(400MHz，DMSO)δ7.0(d，1H)，6.85(s，1H)，6.65(d，1H)，MS(EI)m/e?134(M +)。F) preparation of N-(4-cyano-2-hydroxy-phenyl)-N '-(2-bromophenyl) thiourea.
To 4-cyano-2-hydroxy-aniline (1.0g, add in ethanol 7.5mmol) (20mL) solution isothiocyanic acid (2-bromophenyl) ester (1.0mL, 7.5mmol).After 24 hours, the concentrating under reduced pressure reactant mixture obtains 2.0g (77%) N-(4-cyano-2-hydroxy-phenyl)-N '-(2-bromophenyl) thiourea yellow solid, and this product does not need to be further purified. 1H?NMR(400MHz，DMSO)δ0.8(s，1H)，10.1(s，1H)，9.6(s，1H)，8.7(d，1H)，7.7(d，1H)，7.6(d，1H)，7.4(t，1H)，7.25(d，1H)，7.2(s，1H?and?d，2H)；MS(EI)m/e?229(100)，348(75(M +))，462(30)，695(10)。G) preparation of N-(4-cyano group-2-tertiary butyl dimethyl Si base phenyl)-N '-(2-bromophenyl) thiourea.
0 ℃ to N-(4-cyano-2-hydroxy-phenyl)-N '-(2-bromophenyl) thiourea (3.5g, add in THF 10mmol) (50mL) solution imidazoles (1.0g, 15mmol) and TBSC1 (1.5g, 10mmol).After 1 hour, water (100mL) stops this reaction, and uses the ethyl acetate extraction reactant mixture.The organic layer salt water washing that merges, with anhydrous magnesium sulfate drying and concentrating under reduced pressure, crude product crystallization from ethyl acetate obtains 3.9g (84%) N-(4-cyano group-2-tertiary butyl dimethyl Si base phenyl)-N '-(2-bromophenyl) thiourea yellow solid. 1HNMR(400MHz，DMSO)δ9.9(s，1H)，9.2(s，1H)，8.1(d，1H)，7.7(d，1H)，7.6(d，1H)，7.45(d，1H)，7.4(t，1H)，7.35(s，1H)，7.2(t，1H)；MS(EI)m/e?347(100(M +))，175(40)，461(40)。H) preparation of N-(4-cyano group-2-tertiary butyl dimethyl Si base phenyl)-N '-(2-bromophenyl) carbodiimides.
At 0 ℃ to N-(4-cyano group-2-tertiary butyl dimethyl Si base phenyl)-N '-(2-bromophenyl) thiourea (3.4g, 7.4mmol) dichloromethane (40mL) solution in add triethylamine (3.1mL 22mmol), DMAP (20mg) and mesyl chloride (1.1mL, 15mmol).After 25 minutes, water (100mL) cessation reaction, and use the ethyl acetate extraction reactant mixture, the organic layer salt water washing that merges, with anhydrous magnesium sulfate drying and concentrating under reduced pressure, obtain 3.3g (100%) N-(4-cyano group-2-tertiary butyl dimethyl Si base phenyl)-N '-(2-bromophenyl) carbodiimides yellow solid, this product does not need to be further purified. 1H?NMR(400MHz，DMSO)δ7.7(d.1H)，7.45(d，1H)，7.4(m，4H)，7.15(t，1H)。I) standard method of synthetic diphenylguanidine.4-[[1-(2-bromophenyl)-4,5-dihydro-5-oxo-1H-imidazoles-2-yl] amino]-preparation of 3-hydroxy benzonitrile.
To N-(4-cyano group-2-tertiary butyl dimethyl Si base phenyl)-N '-(2-bromophenyl) carbodiimides (112mg, 0.26mmol) acetonitrile (2mL) solution in add diisopropylethylamine (0.10mL 0.57mmol) and glycine hydrochloride ethyl ester (40mg, 0.29mmol).After 30 minutes, enriched mixture at low temperatures.(0.29mL 0.29mmol) dilutes thick residue with THF (1mL), methanol (0.1mL) and TBAF at 0 ℃.After 5 minutes, water (2mL) cessation reaction, and use the ethyl acetate extraction reactant mixture.The organic layer salt water washing that merges is with anhydrous magnesium sulfate drying and concentrating under reduced pressure.Crude product is the recrystallization purifying crude product from dichloromethane and hexane, obtains 70mg (73%) chocolate brown powder shape 4-[[1-(2-bromophenyl)-4,5-dihydro-5-oxo-1H-imidazoles-2-yl] amino]-the 3-hydroxy benzonitrile. 1H?NMR(400MHz，MeOD)δ7.6(1H，d)，7.55(1H，d)，7.4(1H，s)，7.3(2H，dd)，7.0(2H，m)；MS(EI)m/e?372(100(M +)。K) N-(4-cyano-2-hydroxy-phenyl)-N '-(2-bromophenyl)-N " preparation of (2-ethoxy) guanidine.
By standard method, with N-(4-cyano group-2-tertiary butyl dimethyl Si base phenyl)-N '-(2-bromophenyl) carbodiimides (105mg, 0.24mmol), diisopropylethylamine (45 μ L, 0.26mmol), ethanolamine (16 μ L, 0.26mmol) and TBAF (0.53ml, 0.53mmol) in THF (2mL) and methanol (0.1mL), react, obtain N-(4-cyano-2-hydroxy-phenyl)-N '-(2-bromophenyl)-N " (2-ethoxy) guanidine of 52mg (57%) chocolate brown powder shape. 1H?NMR(400MHz，DMSO)δ7.55(2H，m)，7.2(1H，t)，7.1(1H，d)，7.05(1H，s)，6.95(1H，d)，6.85(1H，t)；MS(EI)m/e?376(100(M +))，490(20)。L) N-(4-cyano-2-hydroxy-phenyl)-N '-(2-bromophenyl)-N " preparation of (chloromethanes sulfonyl) guanidine.
By standard method; with N-(4-cyano group-2-tertiary butyl dimethyl Si base phenyl)-N '-(2-bromophenyl) carbodiimides (220mg; 0.51mmol), diisopropylethylamine (63 μ L; 0.56mmol), chloromethyl sulfonamide (72mg; 0.56mmol) and TBAF (0.13mL; 0.13mmol) in THF (1mL) and methanol (0.1mL), react, obtain N-(4-cyano-2-hydroxy-phenyl)-N '-(2-bromophenyl)-N " (chloromethanes sulfonyl) guanidine of 16mg (32%) chocolate brown powder shape. 1H?NMR(400MHz，MeOD)δ7.85(1H，d)，7.7(1H，d)，7.5(1H，d)，7.4(1H，t)，7.25(1H，t)，7.15(1H，d)，7.05(1H，s)，4.7(2H，s)；MS(EI)m/e?887(100(Mx2))，490(20)。M) N-(4-cyano-2-hydroxy-phenyl)-N '-(2-bromophenyl)-N " preparation of (2,2 dimethoxy-ethyl) guanidine.
By standard method, with N-(4-cyano group-2-tertiary butyl dimethyl Si base phenyl)-N '-(2-bromophenyl) carbodiimides (250mg, 0.58mmol), diisopropylethylamine (72 μ L, 0.64mmol), 2,2-dimethoxy-ethylamine (70 μ, 0.64mmol) and TBAF (0.70mL, 0.70mmol) reaction in THF (6mL) and methanol (0.1mL), obtain N-(4-cyano-2-hydroxy-phenyl)-N '-(2-bromophenyl)-N " (2, the 2-dimethoxy-ethyl) guanidine of 170mg (70%) chocolate brown powder shape. 1H?NMR(400MHz，MeOD)δ7.6(1H，m)，7.5(1H，d)，7.15(1H，t)，7.1(1H，d)，7.0(1H，s)，6.9(1H，d)，6.8(1H，t)，4.45(1H，t)，3.3(6H，s)；MS(EI)m/e?420(100(M +))。N) 4-[[1-(2-bromophenyl)-4,5-dihydro-1H-imidazoles-2-yl] amino]-preparation of 3-hydroxy benzonitrile.
At room temperature to N-(4-cyano-2-hydroxy-phenyl)-N '-(2-bromophenyl)-N " (2-ethoxy) guanidine (46.2mg, add in THF .12mmol) (2mL) solution triphenyl phasphine (140mg, 0.53mmol) and DEAD (41 μ L .26mmol).2.5 after hour, water (1mL) cessation reaction, and use the ethyl acetate extraction reactant mixture.The organic layer salt water washing that merges is with anhydrous magnesium sulfate drying and concentrating under reduced pressure.Thick residue obtains the 4-[[1-(2-bromophenyl)-4 of 28 mg (65%) chocolate brown powder shape, 5-dihydro-1H-imidazoles-2-yl with column chromatography (ethyl acetate solution of 10%MeOH) purification] amino]-the 3-hydroxy benzonitrile. 1H?NMR(400MHz，CDCl3)δ7.6(1H，d)，7.4(2H，m)，7.2(1H，t)，7.0(3H，d?and?s)，3.95(2H，t)，3.75(2H，t)；MS(EI)m/e?358(100(M +))。O) 4-[[4-(2-bromophenyl)-4,5-dihydro-1,1-diepoxy-1,2,4-thiadiazoles-3-yl] amino]-preparation of 3-hydroxy benzonitrile.
At room temperature to N-(4-cyano-2-hydroxy-phenyl)-N '-(2-bromophenyl)-N " (chloromethanes sulfonyl) guanidine (220mg, add in DMF 0.39mmol) (4mL) solution sodium hydride (20mg, 0.78mmol).After 24 hours, water (5mL) cessation reaction, and use the ethyl acetate extraction reactant mixture.The organic layer salt water washing that merges is with anhydrous magnesium sulfate drying and concentrating under reduced pressure.Thick residue obtains the 4-[[4-(2-bromophenyl)-4 of 100mg (63%) chocolate brown powder shape, 5-dihydro-1,1-diepoxy-1,2,4-thiadiazoles-3-yl with column chromatography (hexane solution of 75% ethyl acetate) purification] amino]-the 3-hydroxy benzonitrile. 1H?NMR(400MHz，CDCl3)δ8.1(1H，d)，7.85(1H，d)，7.7(1H，d)，7.6(1H，t)，7.5(1H，t)，7.2(1H，d)，7.0(1H，s)，4.75(2H，q)；MS(EI)m/e?406(100(M -))。P) 4-[[1-(2-bromophenyl)-1H-imidazoles-2-yl] amino]-preparation of 3-hydroxy benzonitrile.
" (120mg adds pTSA (1mg) in acetone 0.28mmol) (1mL) solution to (2, the 2-dimethoxy-ethyl) guanidine at room temperature to N-(4-cyano-2-hydroxy-phenyl)-N '-(2-bromophenyl)-N.After 24 hours, water (5mL) cessation reaction, and use the ethyl acetate extraction reactant mixture.The organic layer salt water washing that merges is with anhydrous magnesium sulfate drying and concentrating under reduced pressure.Thick residue column chromatography (100% ethyl acetate) purification, obtain 4-[(1-(2-the bromophenyl)-1H-imidazoles-2-yl of 12mg (12%) chocolate brown powder shape] amino]-4-[[1-(2-bromophenyl)-4 of 3-hydroxy benzonitrile and 4mg (4%) chocolate brown powder shape, 5-dihydro-5-methoxyl group-1H-imidazoles-2-yl] amino]-the 3-hydroxy benzonitrile.
4-[[1-(2-bromophenyl)-1H-imidazoles-2-yl] amino]-the 3-hydroxy benzonitrile: 1H NMR (400MHz, MeOD) δ 7.45 (2H, t), 7.35 (1H, d), 7.3 (1H, s), 7.25 (1H, d), 7.15 (1H, t), 7.1 (1H, s), 7.0 (1H, s), 6.75 (1H, t); MS (EI) m/e 356 (100 (M +)).
4-[[1-(2-bromophenyl)-4,5-dihydro-5-methoxyl group-1H-imidazoles-2-yl] amino]-the 3-hydroxy benzonitrile: 1H NMR (400MHz, MeOD) δ 7.65 (1H, t), 7.55 (1H, d), 7.25 (1H, t), 7.2 (2H, s and d), 7.05 (1H, d), 6.95 (1H, t), 5.8 (1H, d), 3.8 (1H, dd), 3.5 (1H, dd), 3.25 (3H, s); MS (EI) m/e 388 (100 (M +)).
Therapeutic Method
The compound or pharmaceutically acceptable salt thereof of formula (I) can be used for preparing the medicine that is used for preventing or treating the mankind or any morbid state of other mammal, these morbid states are because the too much or irregular institute of the IL-8 cytokine that mammalian cell produces causes or increases the weight of, such as, but not limited to: mononuclear cell and/or macrophage, or other and IL-8 α or beta receptor, be also referred to as the chemotactic factor that I type or II receptor combine.
Therefore, the invention provides a kind of Therapeutic Method of chemokine mediated diseases, wherein, chemotactic factor combines with IL-8 α or beta receptor, and the method comprises formula (I) compound or pharmaceutically acceptable salt thereof of taking effective dose.Especially, chemotactic factor is IL-8, GRO α, GRO β, GRO γ, NAP-2 or ENA-78.
For the purposes of this paper, formula (I) and chemical compound (II) all have same dosage, and the prescription that resembles formula (I) chemical compound is interchangeable.
Formula (I) chemical compound of using q.s is to suppress cytokine function, the function of IL-8, GRO α, GRO β, GRO γ, NAP-2 or ENA-78 particularly, make it to turn down biology the normal level of physiological function, or adjust in some sense and be lower than normal level, to improve morbid state.For example in the context of the present invention, the generation of the abnormal level of IL-8, GRO α, GRO β, GRO γ, NAP-2 or ENA-78 is made up of following: (i) free IL-8 horizontal exceeding or equal 1 pik/mL; Relevant IL-8, GRO α, GRO β, GRO γ, NAP-2 or the ENA-78 of (ii) any cell surpasses the normal physiological level; Or (iii) the existence of IL-8, GRO α, GRO β, GRO γ, NAP-2 or ENA-78 is higher than the basic horizontal of IL-8, GRO α, GRO β, GRO γ, NAP-2 or ENA-78 in cell or tissue respectively.
The numerous disease state is arranged, and it is superfluous or irregularly increase the weight of and/or cause disease wherein to produce IL-8.Chemokine mediated disease comprises psoriasis, atopic dermatitis, arthritis, asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, inflammatory bowel, Crohn disease, ulcerative colitis, apoplexy, septic shock, endotoxin shock, the negative pyemia of Pueraria lobota Lan Shi, toxic shock syndrome, heart and kidney reperfusion injury, glomerulonephritis, thrombosis, graft versus host disease, Alzheimer, allograft rejection, malaria, restinosis, angiogenesis, atherosclerosis, osteoporosis, gingivitis or bad hematopoietic stem cell discharge.
These diseases mainly are grown to feature with a large amount of neutrophil infiltration, T cellular infiltration or neovascularity, and relevant with IL-8, GRO α, GRO β, GRO γ or NAP-2 generation increase, it is responsible for making the directional growth of neutrophilic granulocyte to areas of inflammation chemotactic or endotheliocyte.With other struvite cytokine (IL-1, TNF, with IL-6) compare, IL-8, GRO α, GRO β, GRO γ or NAP-2 have unique release characteristics that impels neutrophilic granulocyte chemotactic, enzyme, and it includes but not limited to discharge elastoser and superoxides produces and activation.α chemotactic factor and particularly GRO α, GRO β, GRO γ or NAP-2 that I or II receptor by IL-8 works, thus the neovascularization of tumor can be impelled by the directional growth of impelling endotheliocyte.Therefore, will cause the direct minimizing of neutrophil infiltration to the inhibition of inductive chemotactic of IL-8 or activation.
Nearest evidence has also shown the effect of chemotactic factor in the HIV treatment of infection, Littleman etc., and Nature 381, pp 661 (1996) and Koup etc., Nature 381, and pp 667 (1996).
The present invention also provides a kind of Therapeutic Method, with the chemokine receptor anagonists compounds for treating acute state (setting) of formula (I), and is used for those are considered to susceptible individual prevention CNS damage.
Comprise the open or penetrating trauma of head in the CNS of this definition damage, such as operation, or closure head wound, as the damage in head zone.Within this definition, also comprise ischemic stroke, particularly brain area.
Ischemic stroke can be defined as the focus neurological disorders that the blood supply deficiency by specific brain area causes, and normally result is the atherosis obturation of blood vessel embolism, thrombosis or local intra-arterial.Demonstrate struvite effect of cytokines in this zone, the invention provides a kind of method of possible these damages of treatment.To such as these acute injuries, it is feasible almost not having relevant treatment.
TNF-α is a kind of cytokine with proinflammatory effect, and it comprises the expression of endothelial leukocyte adhesion molecule.Leukocyte infiltration is to the ischemic brain injury zone, and therefore suppress or reduce the chemical compound of TNF level will be useful to the treatment of ischemic brain injury.See Liu etc., Stroke, Vol.25., No.7, pp 1481-88 (1994), its disclosed content is hereby incorporated by.
The model of CHI and with the treatment of blended 5-LO/CO agent at Shohami etc., J.of Vaisc ﹠amp; Clinical Physiology and Pharmacology, Vol.3, No.2, pp.99-107 discusses in (1992), and its disclosed content is hereby incorporated by.Find that in those animals of being treated the treatment that alleviates edema formation can improve the function result.
Formula (I) chemical compound of taking q.s with suppress with such as reduction neutrophilic granulocyte chemotactic and the IL-8 α of activation or combining of beta receptor.Formula (I) chemical compound is the discovery of the bonded inhibitor of IL-8, be based on formula described herein (I) chemical compound extracorporeal receptor in conjunction with the test in effect.In some instances, the chemical compound that demonstrates formula (I) is the double inhibitor of the IL-8 receptor of reorganization I type and II type.Preferably, this chemical compound only is a kind of inhibitor of receptor, more preferably the inhibitor of II type IL-8 receptor.
The term that this paper uses " disease or the morbid state of IL-8 mediation " refers to any He all morbid states, wherein IL-8, GRO α, GRO β, GRO γ, NAP-2 or ENA-78 play effect, perhaps by producing IL-8, GRO α, GRO β, GRO γ, NAP-2 or ENA-78 itself, perhaps cause that by IL-8, GRO α, GRO β, GRO γ, NAP-2 or ENA-78 other monokine discharges, such as, but not limited to IL-1, IL-6 or TNF.A kind of morbid state, wherein for example IL-1 is a main component, and therefore its generation or effect then be considered to the IL-8 disease states mediated corresponding to increase or the minimizing of IL-8.
The term " chemokine mediated disease or morbid state " that this paper uses refers to any He all morbid states, wherein work, such as but not limited to IL-8, GRO α, GRO β, GRO γ, NAP-2 or ENA-78 with IL-8 α or the bonded chemotactic factor of beta receptor.This comprises a kind of morbid state, and wherein IL-8 works, or passes through to produce IL-8 itself, or causes that by IL-8 other monokine discharges, such as, but not limited to IL-1, IL-6 or TNF.A kind of morbid state, wherein, for example IL-1 is a main component, and therefore its generation or effect then be considered to the IL-8 disease states mediated corresponding to increase or the minimizing of IL-8.
The term " cytokine " that this paper uses " refer to influence any excretory polypeptide of cell function, and be the molecule of in immunity, inflammation or hemopoietic reaction, adjusting cell-cell interaction.Cytokine includes but not limited to: monokine and lymphokine, no matter they by which cell are produced.For example: monokine is often referred to by producing such as macrophage and/or monocytic mononuclear cell and excretory.But many other cells also produce monokine, such as natural killer cell, fibroblast, basophilic leukocyte, neutrophilic granulocyte, endotheliocyte, the star-like cell of brain, marrow stromal cell, keratinization of epidermis cell and bone-marrow-derived lymphocyte.Lymphokine is often referred to by lymphocyte and produces.The example of cytokine includes, but are not limited to interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin 8 (IL-8), tumor necrosis factor-alpha (TNF-α) and tumor necrosis factor (TNF-β).
The term " chemotactic factor " that this paper uses refers to influence any excretory polypeptide of cell function, and is the molecule of adjusting cell-cell interaction in immunity, inflammation or hemopoietic reaction, with term " cytokine " above " similar.Chemotactic factor is mainly secreted by striding theca cell (celltrausmembranes), and causes the chemotaxis and the activation of particular white blood cells and leukocyte, neutrophilic granulocyte, mononuclear cell, macrophage, T-cell, B-cell, endotheliocyte and smooth muscle cell.The example of chemotactic factor includes but not limited to: IL-8, GRO α, GRO β, GRO γ, NAP-2, ENA-78, IP-10, MIP-1 α, MIP-β, PF4 and MCP1,2 and 3.
For the compound or pharmaceutically acceptable salt thereof of application formula (I), the pharmacy practice according to standard is mixed with pharmaceutical composition with it usually in treatment.Therefore the invention still further relates to and comprise effective, formula (I) chemical compound of nontoxic amount and the pharmaceutical composition of pharmaceutically suitable carrier or diluent.
The chemical compound of formula (I), its officinal salt and as above blended pharmaceutical composition can be used by any route of administration easily, for example: oral, local application, parenterai administration or suction.The chemical compound of formula (I) can be used the pharmaceutical carriers of the chemical compound of formula (I) and standard by conventional method in conjunction with making easily dosage form.The chemical compound of formula (I) can also and a kind of known second kind of therapeutical active compound take with dosage combination easily.These methods can relate to mixes suitable composition, granulate and suppresses or be dissolved in the purpose preparation.Should recognize that pharmacy can accept the amount of the form of characteristic or diluent and the active component that characteristic is united use, route of administration and other well-known variablees and arrange.Say that on the meaning compatible carrier must be " acceptable " and can be not toxic to its receptor with other composition of preparation.
For example, pharmaceutical carrier can be solid or liquid, and the typical solid carrier is lactose, Gypsum Fibrosum powder, sucrose, Pulvis Talci, gel, agar, colloid, Radix Acaciae senegalis, magnesium stearate, stearic acid etc.Exemplary of liquid carriers is syrup, Oleum Arachidis hypogaeae semen, olive oil, water etc.Equally, carrier or diluent can comprise well-known time delay material in this area, such as: separately or contain the glyceryl monostearate or the distearin of paraffin.
Operable medicament forms is very extensive, and therefore, if what use is a kind of solid carrier, preparation can be prepared into tablet, with powder or become the bead form or put into hard capsule with lozenge or lozenge form.The amount of solid carrier can great changes have taken place, but preferably from about 25mg to about 1g.When the using liquid carrier, preparation can be syrup, Emulsion, soft capsule, sterile injectable liquid, as ampoule or non-aqueous suspension.
The chemical compound of formula (I) can local application, promptly by non-systemic administration.This comprises that the chemical compound of formula (I) uses epidermis or cheek chamber outward and this mixture is splashed into ear, eye and nose, and this chemical compound will can significantly not enter blood like this.In contrast, systemic administration refers to oral cavity, intravenous, intraperitoneal and intramuscular administration.
The preparation that is applicable to local application comprises and is suitable for liquid or the semi-liquid preparations that transdermal reaches inflammation part, such as liniment, lotion, cream, ointment or paste be applicable to the drop of eye, ear or nose medication.For local application, active component can comprise 0.001% to 10%w/w in weight of formulation, and for example from 1% to 2%.But it can contain the 10%w/w up to preparation, but preferably is less than 5%w/w, more preferably 0.1% arrives 1%w/w.
Lotion of the present invention comprises those that are suitable for skin or ophthalmic applications.Eye lotions can comprise the optional aseptic aqueous solution that contains antibacterial and can be with the preparation method preparation that is similar to drop.The lotion or the liniment that are used for skin can also comprise that a kind of acceleration is dry and make the refrigerative reagent of skin, such as ethanol or acetone, and/or a kind of wetting agent, as glycerol or a kind of oil, as Oleum Ricini or Oleum Arachidis hypogaeae semen.
Cream of the present invention, ointment or paste are the semi-solid preparations of external active component.These preparations can be by the active component of finely divided or powder type, separately or in the solution or suspension of water or on-aqueous liquid, mixes with oils and fats or non-oils and fats substrate and makes with suitable machinery help.Substrate can comprise hydrocarbon such as hard, soft or liquid paraffin, glycerol, Cera Flava, metallic soap; Cement; The oil of natural origin such as almond oil, Semen Maydis oil, Oleum Arachidis hypogaeae semen, Oleum Ricini or olive oil; Lanoline or derivatives thereof or fatty acid such as stearic acid or oleic acid and alcohol are such as propylene glycol or macrogel.Preparation can comprise any suitable surfactant such as anion, cation or non-ionic surface active agent such as Isosorbide Dinitrate or its polyoxyethylene deriv.Preparation can comprise that suspending agent such as natural gum, cellulose derivative or inorganic matter such as silicaceous silicon and other compositions are such as lanoline.
Drop of the present invention comprises sterilized water or oil solution or suspension, and can be by preparing in the aqueous solution that active component is dissolved into suitable antibacterial and/or antifungal and/or other any suitable preservatives, and preferably includes surfactant.Then resulting solution is made it clarification by filtration, transfer to proper container and seal then, by autoclaving or maintain sterilization 98-100 ℃ of half an hour.In addition, this solution can also be transferred in the container by filtration sterilization and with aseptic technique.Being suitable for being included in the antibacterial in the drop and the example of antifungal is phenylmercuric nitrate or phenylmercuric acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01%).The suitable solvent that is used to prepare oily solution comprises glycerol, rare ethanol and propylene glycol.
The chemical compound of formula (I) can the parenteral medication, promptly by intravenous, intramuscular, subcutaneous, intranasal, internal rectum, intravaginal or intraperitoneal administration.Usually preferred parenteral medication is subcutaneous and the intramuscular form.The suitable dosage forms that is applicable to this application method can prepare by routine techniques.The chemical compound of formula (I) can also pass through inhaled medication, promptly sucks by intranasal and oral cavity.Suitable dosage forms such as the aerosol or the metered dose inhaler that are applicable to this application method can prepare by routine techniques.
For all application processes of formula disclosed herein (I) chemical compound, every day the oral dose scheme optimization from about 0.01 to about 80mg/kg body weight.Every day the parenteral dosage preferably from about 0.001 to about 80mg/kg body weight.Every day, local application's dosage was preferably from 0.1mg to 150mg, medication every day 1 to 4 time, preferred 2 or 3 times.Every day inhaled medication dosage preferably from about 0.01mg/kg to about 1mg/kg.Those skilled in the art recognizes that also the optimised quantity of the individual dose of formula (I) chemical compound or officinal salt will depend on nature and extent, dosage form, route of administration and the position of disease to be treated and particular patient to be treated with the interval, and this therapeutic regimen can be by technology decision easily.Those skilled in the art also recognizes best therapeutic process, promptly for the treatment of a definite natural law, takes the dosage of formula (I) compound or pharmaceutically acceptable salt thereof every day, can use conventional treatment determination test process by those skilled in the art and determine.
The present invention now will be described by following biology of embodiment.These embodiment just are used to illustrate rather than as the restriction of the scope of the invention.
Biology embodiment
The IL-8 of The compounds of this invention and GRO-α chemotactic factor depression effect are measured with following analyzed in vitro method: receptor binding assay:
From Amersham Corp., Arlington Heights, the IL acquisition [ 125I] IL-8 (human recombinant body), specific activity is 2000 Ci/mmol.Obtain GRO-α from NEN-New EnglandNuclear.All other chemical reagent are AG.High-caliber recombinant human IL-8 α type and β receptor are to express (Holmes etc., Science, 1991,253,1278) as previously mentioned on Chinese hamster ovary cell respectively.(Haour etc., J Biol Chem., 249 pp 2195-2205 (1974)) homogenize the Chinese hamster ovary film according to preceding method.In addition, the buffer that homogenizes changes 10mM Tris-HCL, 1mM MgSO4,0.5mM EDTA (ethylenediaminetetraacetic acid), 1mM PMSF (α-tosyl fluorine), 0.5mg/L leupeptin into, and pH 7.5.Use bovine serum albumin as standard with Pierce Co. microanalysis test kit (Pierce Co.micro-assay kit), measure the concentration of memebrane protein.All analyses are all carried out in 96 hole micropore flat boards.Each reactant mixture contains in 20mM Bis-Trispropane and 0.4mM Tris HCl buffer (pH 8.0) 125I IL-8 (0.25nM) or 125The IL-8R β film of the IL-8R α of IGro-α and 0.5 μ g/mL or 1.0 μ g/mL contains 1.2mM MgSO in the buffer 4, 0.1mM EDTA, 25mM NaCl and 0.03%CHAPS.In addition, add the medicine to be measured be dissolved in advance among the DMSO or chemical compound with the ultimate density that reaches between 0.01nM and 100uM.By adding 125I-IL-8 begins test, after at room temperature 1 hour, with Tomtec 96 hole catchers this flat board collected with containing on the glass fibre filtermat that 1% polymine/0.5%BSA stops, and with 25mMNaCl, 10mMTrisHCl, 1mM MgSO 4, 0.5mM EDTA, 0.03%CHAPS, pH 7.4 washing three times.Then that filter is dry and count on the Betaplate liquid scintillation counter.Recombinant IL-8R α, or the I receptor also refers to non-permission receptor at this paper, and recombinant IL-8R β, or the II receptor refers to permit receptor.
The proof of chemical compound for example IC in IL-8 receptor inhibition licensing model in all formulas (I) that this paper synthetic chemistry part embodiment 1 to 15 shows 50For about 45 to approximately＜1 μ g/mL.In test-compound, find that also embodiment 1 to 12 is GRO-α binding inhibitors of about par.Chemotactic is analyzed:
The vitro inhibition characteristic of these chemical compounds is measured with neutrophilic granulocyte chemotaxis analytical method, as at Current Protocols in Immunology, and Vol I, Suppl 1, and Unit6.12.3 is described, and its disclosure all is incorporated herein by reference at this.As at CurrentProtocols in Immunology, Vol I, Suppl 1, and Unit 7.23.1 is described, separates neutrophilic granulocyte from human blood, and its disclosure all is incorporated herein by reference at this.With chemical inhibitor IL-8, GRO-α, GRO-β, GRO-γ and NAP-2 insert porous chambers 48 (NeuroProbe, Cabin John, bottom compartment MD), concentration is 0.1～100nM.Polycarbonate filter with 5um between two Room is separated.When test during chemical compound of the present invention, just before last chamber adding cell and mixing with cells (0.001-1000nM).The 5%CO that contains in humidity 2Couveuse in continue hatching about 45-90 minute at about 37 ℃.Last in the incubation period, the top side is removed and washed to polycarbonate membrane, (IL USA) dyes film for BaxterProducts, McGaw Park to use Diff Quick colouring method then.Chemotactic is counted with microscopic visual measurement to the cell of chemotactic factor.Usually, each 4 zone of sample counting, these digital averages are as the par of migrating cell.Each sample survey three times and each chemical compound retest at least 4 times.Do not add chemical compound for specific cells (positive control cell), these cells have the maximum chemotactic response of cell.Under the situation of need negative control (not irriate), the bottom compartment does not add chemotactic factor.Difference between positive control and the negative control has been represented the chemotactic activity of cell.Elastoser discharges to be analyzed:
The ability of test The compounds of this invention to stoping elastoser to discharge from human neutrophil.According to Current Protocols in Immunology Vol I, from human blood, isolate neutrophilic granulocyte described in Suppl 1 Unit7.23.1.(NaCl 118, and KCl 4.56, NaHCO will to be suspended in Ringer ' sSolution 325, KH 2PO 41.03 glucose 11.1, HEPES 5 mM, pH 7.4) in PMNs 0.88 * 10 6Cell is put into 96 hole flat boards, every pore volume 50ul.To this dull and stereotyped 50ul testing compound (0.001-1000nM), cytochalasin B 50ul (20ug/ml) and Ringers buffer 50ul of adding.Adding before final concentration is 0.01-1000nM IL-8, GRO α, GRO β, GRO γ or NAP-2, with these cell incubations (37 ℃, 5%CO 2, 95%RH) 5 minutes.Reaction continues 45 minutes, removes with 96 hole flat boards centrifugal (800 * g 5 minutes) and with the 100ul supernatant then.This supernatant is joined in another 96 hole flat board, and adding final concentration subsequently is artificial elastin laminin zymolyte (MeOSuc-Ala-Ala-Pro-Val-AMC, Nova Biochem, La Jolla, phosphate buffer CA) of 6ug/ml.Immediately flat board is inserted 96 hole panel fluorescent readers (Cytofluor 2350, Millipore, Bedford, MA) in, the method for pressing J.Biol Chem 254 4027 (1979) such as Nakajima was with 3 minutes record data at interval.The amount of the elastoser that discharges from PMNs can be calculated by the degradation speed of measuring MeOSuc-Ala-Ala-Pro-Val-AMC.TNF-α in traumatic brain injury analyzes:
The check that this analytical method provides tumor necrosis factor mRNA to express in rat specific brain regions zone, traumatic brain injury (TBI) is hit by the experimental side fluidity that causes in this brain zone.Grow up Sprague-Dawley rat (n=42) with pentobarbital sodium anesthesia (60mg/kg, lumbar injection) and be subjected to moderate side liquid and hit brain injury (2.4atm.), it is centered close to left side temporo napex cortex (n=18), or " simulation " handled, and (not damaged anesthesia is also performed the operation, n=18).The damage 1,6 and 24 hour after with the animal sacrificed by decapitation, take out brain, preparation left side (hindering side) top cortex (LC), to the tissue samples of corresponding close region (RA), left hippocampus (LH) and the right side Hippocampus (RH) of near the cortex (LA) the top cortex of the corresponding zone of right side of face cortex (RC), damage, right side cortex.Separate total RNA and implement Northern marking hybridization and carry out quantitatively with respect to TNF-α positive control RNA (macrophage=100%).Injured side hemisphere in the time of injured back 1 hour is observed (104 ± 17% of positive control in LH, compare p＜0.05 with the simulation group), the remarkable increase of (105 ± 21%, p＜0.05) and (69 ± 8%, p＜0.01) TNF α mRNA expression in LA in LC.Also observed in LH (46 ± 8%, p＜0.05) in back 6 hours in wound, (30 ± 3%, p＜0.01) and (32 ± 3%, p＜0.01) TNF-α mRNA expresses in LA increase in LC, just disappeared in back 24 hours in wound.At offside hemisphere, in wound back 1 hour, in RH (46 ± 2%, p＜0.01), among the RC among (4 ± 3%) and the RA (22 ± 8%), in back 6 hours RH of wound among (28 ± 11%), the RC among (7 ± 5%) and the RA (26 ± 6%, p＜0.05) expression of TNF-α mRNA increases, but does not then have in back 24 hours in wound.Simulation group (not damaged operation) or blank animal, at any time, no matter which side hemisphere, the consistent change that TNF-α mRNA expresses all do not observed in 6 brain zones.After these results are presented at other sagittal plane liquid strike brain injury, there are temporary transient TNF-α mRNA to express in the specific brain regions district and change, comprise the variation of non-wound hemisphere.Because TNF-α can induce nerve growth factor (NGF) and stimulate the release of other cytokines from the star-like cell of activatory brain, the change of TNF-α gene expression all plays an important role in the acute and reproducibility of CNS wound is responded after the wound.The CNS damage model of IL-β mRNA
This analytical method is expressed as feature with the regionality of interleukin-1 ' beta ' (IL-1 β) mRNA in specific brain regions district after hitting brain injury (TBI) at rat experiment side liquid.The Sprague-Dawley rat (n=42) that grows up is anaesthetized (60mg/kg with pentobarbital sodium, lumbar injection) and suffer moderate side liquid to hit brain injury (2.4atm.), it is centered close to left side temporo top cortex (n=18), or " simulation " handles (not damaged anesthesia and operation).The damage 1,6 and 24 hour after with the animal sacrificed by decapitation, take out brain, preparation left side (hindering side) top cortex (LC), near the cortex (LA) the top cortex of the corresponding zone of right side of face cortex (RC), damage, right side cortex to the tissue samples of answering close region (RA), left hippocampus (LH) and right side Hippocampus (RH).Separate total RNA and implement the hybridization of the Northern marking, the amount that obtains cerebral tissue IL-1 β mRNA is represented with the percentage ratio of the relative radioactivity of the positive macrophage RNA of the IL-1 β of load on same gel.At brain injury after 1 hour, at injured side hemisphere, observe (20.0 ± 0.7% of positive control, n=6 among the LC, compare p＜0.05 with simulated animal), among the LH (24.5 ± 0.9%, p＜0.05) expression of (21.5 ± 3.1%, p＜0.05) IL-1 β mRNA has significantly and significant increasing and among the LA, hinders the back by 6 hours, in LC (4.0 ± 0.4%, n=6, p＜0.05) (5.0 ± 1.3%, p＜0.05) above-mentioned observe phenomena still exists and among the LH.In simulation or blank animal, not in of the expression of any relevant brain regional observation to IL-1 β mRNA.After these results are presented at TBI, be upset in the temporary transient expression part of specific brain regions district IL-1 β mRNA.The cytokine that these are regional works after wound such as the variation of IL-1 β.
All publications of quoting in this manual include but not limited to that patent and patent application are hereby incorporated by, and at length and are individually pointed out to be incorporated herein by reference in full as each independent publication.
The foregoing description full disclosure the present invention, comprise its preferred embodiment.In the scope that the improvement and the improvement of this special disclosed embodiment belongs to following claims.If further do not elaborate, it is believed that those skilled in the art can use the front and describe, farthest utilize the present invention.Therefore, embodiment will be only explains as an illustration herein, does not limit the scope of the invention going up all in all senses.The patent rights that the present invention is claimed or the particular content of royalty right such as hereinafter qualification.

Claims (5)

1. formula (I) chemical compound
Figure A0080813300021
Wherein:
R is OH, SH, NHSO 2R d
R dBe NR 6R 7, alkyl, aryl C 1-4Alkyl, aryl C 2-4Thiazolinyl, heteroaryl, heteroaryl C 1-4Alkyl, heteroaryl C 2-4Thiazolinyl, heterocyclic radical, heterocyclic radical C 1-4Alkyl, wherein aryl, heteroaryl and heterocycle all can be optionally substituted;
R 6And R 7Be hydrogen or C independently 1-4Alkyl group, or R 6And R 7Form 5 to 7 yuan of rings together with the nitrogen that is attached thereto, this ring can be chosen wantonly and comprise the hetero atom that another is selected from oxygen, nitrogen or sulfur, and this ring can be optionally substituted;
R 1Independently be selected from hydrogen, halogen, nitro, cyano group, halo C 1-10Alkyl, C 1-10Alkyl, C 2-10Thiazolinyl, C 1-10Alkoxyl, halo C 1-10Alkoxyl, azide, (CR 8R 8) qS (O) tR 4, hydroxyl, hydroxyl C 1-4Alkyl, aryl, aryl C 1-4Alkyl, aryloxy group, aryl C 1-4Alkoxyl, heteroaryl, heteroaryl alkyl, heterocyclic radical, heterocyclic radical C 1-4Alkyl, heteroaryl C 1-4Alkoxyl, aryl C 2-10Thiazolinyl, heteroaryl C 2-10Thiazolinyl, heterocycle C 2-10Thiazolinyl, (CR 8R 8) qNR 4R 5, C 2-10Thiazolinyl C (O) NR 4R 5, (CR 8R 8) qC (O) NR 4R 5, (CR 8R 8) qC (O) NR 4R 10, S (O) 3H, S (O) 3R 8, (CR 8R 8) qC (O) R 11, C 2-10Thiazolinyl C (O) R 11, C 2-10Thiazolinyl C (O) OR 11(CR 8R 8) qC (O) OR 12, (CR 8R 8) qOC (O) R 11, (CR 8R 8) qNR 4C (O) R 11, (CR 8R 8) qNHS (O) 2R 17, (CR 8R 8) qS (O) 2NR 4R 5, or two R 1Common O-(the CH that forms of part 2) sO-or undersaturated 5 to 6 yuan of rings;
Q is 0 or the integer of 1-10;
T is 0 or 1 or 2 integer;
S is the integer of 1-3;
R 4And R 5Independently be hydrogen, the optional C that replaces 1-4Alkyl, the optional aryl that replaces, the optional aryl C that replaces 1-4Alkyl, the optional heteroaryl that replaces, the optional heteroaryl C that replaces 1-4Alkyl, heterocyclic radical, heterocyclic radical C 1-4Alkyl or R 4And R 5Form 5 to 7 yuan of rings together with the nitrogen that is attached thereto, this ring can be chosen wantonly and comprise the hetero atom that another is selected from oxygen, nitrogen or sulfur;
R 6Be independently selected from: C 2-5Alkyl and C 2-5Thiazolinyl, its all groups can be chosen wantonly independently by following groups one to three replacement: halogen, nitro, halo C 1-4Alkyl, C 1-4Alkyl, amino, list-or two-C 1-4Amine, hydroxyl, C that alkyl replaces 1-4Alkoxyl, NR 9C (O) Ra, S (O) mR a, C (O) NR 6R 7, C (O) OH, C (O) OR a, S (O) 2NR 6R 7, NHS (O) 2R a, and de-carbon outside optional independently contain 1 to 3 NR 9, O, C (O), S, SO or SO 2Part;
Y is independently selected from: hydrogen, halogen, nitro, cyano group, halo C 1-10Alkyl, C 1-10Alkyl, C 2-10Thiazolinyl, C 1-10Alkoxyl, halo C 1-10Alkoxyl, azide, (CR 8R 8) qS (O) tR 4, hydroxyl, hydroxyl C 1-4Alkyl, aryl, aryl C 1-4Alkyl, aryloxy group, aryl C 1-4Alkoxyl, heteroaryl, heteroaryl alkyl, heteroaryl C 1-4Alkoxyl, heterocyclic radical, heterocyclic radical C 1-4Alkyl, aryl C 2-10Thiazolinyl, heteroaryl C 2-10Thiazolinyl, heterocyclic radical C 2-10Thiazolinyl, (CR 8R 8) qNR 4R 5, C 2-10Thiazolinyl C (O) NR 4R 5, (CR 8R 8) qC (O) NR 4R 5, (CR 8R 8) qC (O) NR 4R 10, S (O) 3H, S (O) 3R 8, (CR 8R 8) qC (O) R 11, C 2-10Thiazolinyl C (O) R 11, C 2-10Thiazolinyl C (O) OR 11, C (O) R 11, (CR 8R 8) qC (O) OR 12, (CR 8R 8) qOC (O) R 11, (CR 8R 8) qNR 4C (O) R 11, (CR 8R 8) qNHS (O) 2R d, (CR 8R 8) qS (O) 2NR 4R 5, or two Y part can together form O-(CH 2) sO-or undersaturated 5 to 6 yuan of rings;
N is the integer of 1-3;
M is the integer of 1-3;
R 8Be hydrogen or C 1-4Alkyl;
R 9Be hydrogen or C 1-4Alkyl;
R 10Be C 1-10Alkyl C (O) 2R 8
R 11Be hydrogen, C 1-4Alkyl, the optional aryl that replaces, the optional aryl C that replaces 1-4Alkyl, the optional heteroaryl that replaces, the optional heteroaryl C that replaces 1-4Alkyl, the optional heterocyclic radical that replaces or the optional heterocyclic radical C that replaces 1-4Alkyl;
R 12Be hydrogen, C 1-10Alkyl, the optional aryl that replaces or the optional aryl alkyl that replaces;
R 17Be C 1-4Alkyl, aryl, aryl alkyl, heteroaryl, heteroaryl C 1-4Alkyl, heterocyclic radical or heterocyclic radical C 1-4Alkyl, wherein aryl, heteroaryl and heterocycle all can be chosen wantonly and be substituted;
R aBe alkyl, aryl, aryl C 1-4Alkyl, heteroaryl, heteroaryl C 1-4Alkyl, heterocyclic radical or heterocyclic radical C 1-4Moieties, all these parts all can be optionally substituted.
2. according to the chemical compound of claim 1, this chemical compound is:,
4-[[1-(2-bromophenyl)-4,5-dihydro-5-oxo-1H-imidazoles-2-yl] amino]-the 3-hydroxy benzonitrile,
N-(4-cyano-2-hydroxy-phenyl)-N '-(2-bromophenyl)-N " (2-ethoxy) guanidine,
N-(4-cyano-2-hydroxy-phenyl)-N '-(2-bromophenyl)-N " (chloromethanes sulfonyl) guanidine,
N-(4-cyano-2-hydroxy-phenyl)-N '-(2-bromophenyl)-N " (2, the 2-dimethoxy-ethyl) guanidine,
4-[[1-(2-bromophenyl)-4,5-dihydro-1H-imidazoles-2-yl] amino]-the 3-hydroxy benzonitrile,
4-[[4-(2-bromophenyl)-4,5-dihydro-1,1-diepoxy-1,2,4-thiadiazoles-3-yl] amino]-the 3-hydroxy benzonitrile,
4-[[1-(2-bromophenyl)-1H-imidazoles-2-yl] amino]-the 3-hydroxy benzonitrile,
4-[(S)-1-(2-bromophenyl)-4-isopropyl-5-oxo-4,5-dihydro-1H-imidazoles-2-base is amino]-3-hydroxyl-benzonitrile,
3-[(S)-and 1-(2-bromophenyl)-2-(4-cyano-2-hydroxy-phenyl amino)-5-oxo-4,5-dihydro-1H-imidazol-4 yl]-ethyl propionate,
[(R)-and 1-(2-bromophenyl)-2-(4-cyano-2-hydroxy--phenyl amino)-5-oxo-4,5-dihydro-1H-imidazol-4 yl]-ethyl acetate,
4-[(S)-1-(2, the 3-Dichlorobenzene base)-4-isopropyl-5-oxo-4,5-dihydro-1H-imidazoles-2-base is amino]-the 3-hydroxy benzonitrile,
4-[(S)-1-(2, the 3-Dichlorobenzene base)-4-isobutyl group-5-oxo-4,5-dihydro-1H-imidazoles-2-base is amino]-the 3-hydroxy benzonitrile,
4-[(S)-1-(2, the 3-Dichlorobenzene base)-4-(2-methyl sulphonyl ethyl)-5-oxo-4,5-dihydro-1H-imidazoles-2-base is amino]-the 3-hydroxy benzonitrile,
3-[(S)-and 2-(4-cyano-2-hydroxy-phenyl amino)-1-(2, the 3-Dichlorobenzene base)-5-oxo-4,5-dihydro-1H-imidazol-4 yl]-ethyl propionate,
4-[(S)-1-(2, the 3-Dichlorobenzene base)-4-methyl-5-oxo-4,5-dihydro-1H-imidazoles-2-base is amino]-the 3-hydroxy benzonitrile,
4-[(R)-1-(2, the 3-Dichlorobenzene base)-4-methyl-5-oxo-4,5-dihydro-1H-imidazoles-2-base is amino]-the 3-hydroxy benzonitrile and
4-[[1-(2-bromophenyl)-4,5-dihydro-5-methoxyl group-1H-imidazoles-2-yl] amino]-the 3-hydroxy benzonitrile; Or its suitable acceptable salt.
3. pharmaceutical composition, it contains chemical compound and the pharmaceutically suitable carrier or the diluent of the claim 1 for the treatment of effective dose.
4. the method for a chemokine mediated morbid state of treatment, wherein chemotactic factor is attached on the IL-8 α or beta receptor in the mammal, and this method comprises the general formula compound to the claim 1 of above-mentioned administration effective dose.
5. the method for claim 4, wherein mammal suffers from chemokine mediated disease, and this disease is selected from following chemokine mediated disease: psoriasis, atopic dermatitis, arthritis, asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, inflammatory bowel, Crohn disease, ulcerative colitis, apoplexy, septic shock, endotoxin shock, the negative pyemia of Pueraria lobota Lan Shi, toxic shock syndrome, heart and kidney reperfusion injury, glomerulonephritis, thrombosis, graft versus host disease, Alzheimer, allograft rejection, malaria, restinosis, angiogenesis, atherosclerosis, osteoporosis, gingivitis or bad hematopoietic stem cell discharge.
CN00808133A 1999-05-28 2000-05-26 IL-8 receptor antagaonists Pending CN1352554A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13666599P 1999-05-28 1999-05-28
US60/136,665 1999-05-28

Publications (1)

Publication Number Publication Date
CN1352554A true CN1352554A (en) 2002-06-05

Family

ID=22473833

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00808133A Pending CN1352554A (en) 1999-05-28 2000-05-26 IL-8 receptor antagaonists

Country Status (20)

Country Link
EP (1) EP1180025A4 (en)
JP (1) JP2003500443A (en)
KR (1) KR20020016806A (en)
CN (1) CN1352554A (en)
AR (1) AR029361A1 (en)
AU (1) AU766999B2 (en)
BR (1) BR0010863A (en)
CA (1) CA2374295A1 (en)
CO (1) CO5170528A1 (en)
CZ (1) CZ20014246A3 (en)
HK (1) HK1045256A1 (en)
HU (1) HUP0201302A3 (en)
IL (1) IL146053A0 (en)
MX (1) MXPA01012267A (en)
NO (1) NO20015774D0 (en)
NZ (1) NZ514728A (en)
PL (1) PL351947A1 (en)
TR (1) TR200103354T2 (en)
WO (1) WO2000072840A1 (en)
ZA (1) ZA200109627B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101531621B (en) * 2009-04-14 2012-08-15 厦门康奥克科技有限公司 Method for preparing guanidine compound

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1413302A3 (en) * 1999-07-21 2004-05-12 Kadmus Pharmaceuticals, Inc. Substituted guanidines for the treatment of pain
JP2003525213A (en) * 1999-07-21 2003-08-26 キャドマス ファーマシューティカルズ， インコーポレイテッド Substituted guanidines and uses thereof
US6875759B1 (en) 1999-07-21 2005-04-05 Kadmus Pharmaceuticals Substituted guanidines and the use thereof
WO2002070467A1 (en) 2001-02-26 2002-09-12 4Sc Ag Derivatives of diphenylurea, diphenyloxalic acid diamide and diphenylsulfuric acid diamide and their use as medicaments
DE10109204A1 (en) * 2001-02-26 2002-09-19 4Sc Ag Use of new and known diphenylurea compounds for the preparation of a medicament for the inhibition of intracellular protein-degradation pathway
BRPI0409957A (en) 2003-05-01 2006-04-25 Hoffmann La Roche imidazolin-2-ylaminophenyl amides
CN111885914B (en) * 2017-10-27 2022-05-13 投资健康有限责任公司 Compositions and methods for producing expanded hematopoietic stem cells using fluorene derivatives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US605977A (en) * 1898-06-21 Bruno richard seifert
US1953494A (en) * 1926-08-26 1934-04-03 Ig Farbenindustrie Ag Process of preparing substituted guanidines
US3914306A (en) * 1972-09-22 1975-10-21 Rorer Inc William H Guanidines
US5696290A (en) * 1994-09-12 1997-12-09 Monsanto Company Synthesis of penta-substituted guanidines
EP0809492A4 (en) * 1995-02-17 2007-01-24 Smithkline Beecham Corp Il-8 receptor antagonists
AR008290A1 (en) * 1996-08-15 1999-12-29 Smithkline Beecham Corp NEW COMPOUNDS CONTAINING GUANIDINE USEFUL AS ANTAGONISTS OF IL-8 RECEPTORS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM PROCEDURE FOR THE PREPARATION OF SUCH COMPOUNDS AND PROCEDURE FOR THE PREPARATION OF INTERMEDIARIES.
WO2000072800A2 (en) * 1999-05-28 2000-12-07 Smithkline Beecham Corporation Il-8 receptor antagonists
UY26627A1 (en) * 2000-03-24 2001-09-28 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101531621B (en) * 2009-04-14 2012-08-15 厦门康奥克科技有限公司 Method for preparing guanidine compound

Also Published As

Publication number Publication date
CO5170528A1 (en) 2002-06-27
NO20015774L (en) 2001-11-27
JP2003500443A (en) 2003-01-07
HUP0201302A3 (en) 2003-02-28
KR20020016806A (en) 2002-03-06
MXPA01012267A (en) 2002-07-30
EP1180025A1 (en) 2002-02-20
EP1180025A4 (en) 2002-08-28
NZ514728A (en) 2004-04-30
CZ20014246A3 (en) 2002-05-15
TR200103354T2 (en) 2002-06-21
PL351947A1 (en) 2003-07-14
CA2374295A1 (en) 2000-12-07
IL146053A0 (en) 2002-07-25
AU5169000A (en) 2000-12-18
HK1045256A1 (en) 2002-11-22
AR029361A1 (en) 2003-06-25
NO20015774D0 (en) 2001-11-27
HUP0201302A2 (en) 2002-12-28
AU766999B2 (en) 2003-10-30
BR0010863A (en) 2002-02-19
WO2000072840A1 (en) 2000-12-07
ZA200109627B (en) 2002-11-28

Similar Documents

Publication Publication Date Title
CN1278726A (en) IL-8 receptor antagonists
CZ425598A3 (en) Antagonist of il-8 receptor
CN1454204A (en) IL-8 receptor antagonists
CN1251038A (en) IL-8 receptor antagonists
CZ425698A3 (en) Il-8 receptor antagonist
JP2000513360A (en) IL-8 receptor antagonist
CZ46799A3 (en) Il-8 receptor of antagonists
CN1416339A (en) IL-8 receptor antagonsts
CN1353606A (en) IL-8 receptor antagonists
CN1253501A (en) IL-8 receptor antagonists
CN1352554A (en) IL-8 receptor antagaonists
CN1635979A (en) IL-8 receptor antagonists
CN1356899A (en) IL-8 receptor antagonists
CN1278721A (en) IL-8 receptor antagonists
JP2003527360A (en) IL-8 receptor antagonist
CZ20023192A3 (en) Antagonists of IL-8 receptor
US6248785B1 (en) IL-8 receptor antagonists
CN1424910A (en) IL-8 receptor antagonists
JP2006506404A (en) IL-8 receptor antagonist
JP2000515495A (en) IL-8 receptor antagonist
CN1418096A (en) IL-8 receptor antagonists
WO2000073282A1 (en) Il-8 receptor antagonists
JP2003501472A (en) IL-8 receptor antagonist
CN1494424A (en) IL-8 receptor antagonists
CN1314893A (en) IL-8 receptor antanonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication